Overview
This protocol describes a weekly subcutaneous injection approach aimed at supporting weight and metabolic control through a gradual escalation from 0.25 mg up to 2.4 mg weekly.
Blend Composition
The blend combines two components:
– Cagrilintide: Amylin receptor agonist for appetite control
– Semaglutide: Support for glycemic regulation and metabolic management
Reconstitution
Instructions
1. Draw 3.0 mL of bacteriostatic water using a sterile syringe
2. Inject slowly along the vial wall to minimize foaming
3. Gently swirl — avoid vigorous shaking
4. Store reconstituted solution at 2–8°C, protected from light
Recommended Concentration
– Volume: 3 mL bacteriostatic water
– Resulting concentration: approximately 3.33 mg/mL
Dosage Protocols
Standard/Gradual Approach
| Weeks | Weekly Dose | Units (per injection) |
|---|---|---|
| 1–4 | 0.25 mg | ~7.5 units |
| 5–8 | 0.5 mg | ~15 units |
| 9–12 | 1.0 mg | ~30 units |
| 13–16 | 1.7 mg | ~51 units |
| 17+ | 2.4 mg | ~72 units |
Gradual escalation from initiation to maintenance over 17+ weeks.
Aggressive/Accelerated Approach
| Weeks | Weekly Dose | Units (per injection) |
|---|---|---|
| 1–2 | 0.5 mg | ~15 units |
| 3–6 | 1.0 mg | ~30 units |
| 7–10 | 1.7 mg | ~51 units |
| 11–16 | 2.4 mg | ~72 units |
Faster escalation, reaching 2.4 mg by week 11.
Frequency and Duration
– Frequency: One subcutaneous injection per week
– Cycle duration: 8–16 weeks or more, depending on goals
– Maximum dose: Typically 2.4 mg weekly for maintenance
– Timing: Any time of day; maintain weekly consistency
Storage
– Lyophilized: Freeze until mixing (−20°C)
– Reconstituted: Refrigerate at 2–8°C
– Shelf life: Use within 30 days after reconstitution
– Care: Avoid repeated freeze-thaw cycles
How It Works
This combination agonizes multiple receptors to reduce food intake and helps regulate insulin secretion and blood glucose levels, targeting key hormonal signals for improved weight control and satiety.
Potential Benefits
– Supports weight reduction and improved metabolic markers
– May improve glucose control in certain populations
– Effects related to appetite control and satiety
Side Effects
Common
– Mild nausea
– Gastrointestinal discomfort
– Reduced appetite
Rare
– Injection site irritation
– Headaches
Injection Technique
– Clean vial stopper and skin with alcohol; allow to dry
– Pinch a skin fold; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate; inject slowly and steadily
– Systematically alternate sites (abdomen, thighs, upper arms) to avoid lipohypertrophy
– Do not rub the injection site; apply gentle pressure with gauze if needed
Lifestyle Factors
– Maintain a balanced, protein-rich diet
– Regular physical activity and adequate recovery
– Prioritize sleep and stress management
Important Considerations
– Always use new sterile insulin syringes
– Rotate injection sites
– Maintain consistency; weekly injections produce better results
– Monitor for adverse reactions; consult a professional if concerns arise
– Track progress and adjust dosage as recommended by tolerability
Disclaimer
All content on this page is for research and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before initiating any research protocol. This content is provided solely for educational purposes and does not constitute medical advice, diagnosis, or treatment.